Antidrug AntibodiesAntidrug antibodies (ADAs) were detected in 66% of patients, which coincided with reduced serum MP0533 exposure levels, posing a challenge to treatment efficacy.
Dose Limiting Toxicities3 investigator-assessed DLTs were recorded (2 in DR7 and 1 in DR8), and 1 DLT (fatal pulmonary hemorrhage in context of disseminated intravascular coagulation) in DR8 was confirmed by the Dose Escalation Review Committee, resulting in a TD decrease for subsequent patients in DR8.